BC
ABUS icon

Brookfield Corp’s Arbutus Biopharma ABUS Stock Holding History

Brookfield Corp’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,915,000
Closed -$5.19M – 611
2022
Q2 		$5.19M Sell
1,915,000
-413,054
-18% -$1.06M 0.02% 247
2022
Q1 		$6.94M Buy
2,328,054
+1,135,165
+95% +$3.47M 0.03% 205
2021
Q4 		$4.64M Buy
+1,192,889
New +$4.63M 0.02% 231

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Brookfield Corp's ABUS Position: Q3 2022 in Review

Brookfield Corp sold out of Arbutus Biopharma (ABUS) in Q3 2022, closing a stake of 1,915,000 shares — an estimated $5.19M sold.

Brookfield Corp first reported a position in ABUS in Q4 2021 and held it in 3 quarters. The position peaked at $6.94M in Q1 2022. 127 funds tracked by Wall St. Rank hold ABUS as of Q3 2022.

  • Brookfield Corp reported no remaining Arbutus Biopharma position as of Q3 2022 after selling out during the quarter.
  • Brookfield Corp sold 1,915,000 Arbutus Biopharma shares in Q3 2022, an estimated $5.19M.
  • Brookfield Corp first reported a position in Arbutus Biopharma in Q4 2021 and held it in 3 quarters.
  • Brookfield Corp's Arbutus Biopharma position peaked at $6.94M in Q1 2022.
  • 127 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2022.

Based on Brookfield Corp's 13F filing for Q3 2022, filed 14 Nov 2022.